Sulaiman Al Habib’s net profit up 22% to SAR 788.6 mln in H1 2022; Q2 at SAR 398.1 mln

Sulaiman Al Habib’s net profit up 22% to SAR 788.6 mln in H1 2022; Q2 at SAR 398.1 mln

07/08/2022 Argaam Exclusive

View other reports

Dr. Sulaiman Al Habib Medical Services Group (HMG) posted a 22% rise in H1 2022 net profit after Zakat and tax to SAR 788.6 million, from SAR 644.4 million in the year-earlier period.



Financials (M)

Item 6m 2021 6m 2022 Change‬
Revenues 3,446.00 4,004.87 16.2 %
Gross Income 1,100.44 1,329.44 20.8 %
Operating Income 689.36 836.84 21.4 %
Net Income 644.40 788.64 22.4 %
Average Shares 350.00 350.00 -
EPS (Riyals) 1.84 2.25 22.4 %

The net profit was spurred by a 16.22% year-on-year (YoY) rise in revenue to SAR 4.004 billion amid continued growth in all segments. The revenue growth was primarily bolstered by the hospital segment, due to the increase in the number of patients and inpatient occupancy. This growth reflected positively on the pharmacy segment sales on an annual basis.

 

In Q2 2022, net profit after Zakat and tax climbed 22% to SAR 398.13 million from SAR 325.40 million in the prior-year period.



Current Quarter Comparison (M)

Compared With The
Item Q2 2021 Q2 2022 Change‬
Revenues 1,751.21 2,014.01 15.0 %
Gross Income 551.02 670.88 21.8 %
Operating Income 339.73 414.75 22.1 %
Net Income 325.40 398.13 22.4 %
Average Shares 350.00 350.00 -
EPS (Riyals) 0.93 1.14 22.4 %

When compared to Q1 2022, net profit grew by 2% from SAR 390.51 million.

 

Shareholders’ equity, after minority interest, rose 9.75% to SAR 5.593 billion as of June 30, 2022, from SAR 5.096 billion in the corresponding period last year

View More Financial Results

 


Financial results (Million)

Period Revenues Change Gross Income Change Net Income Change EPS(Riyal)
Q1 2013 - - - - - - -
Q2 2013 - - - - - - -
Q3 2013 - - - - - - -
Q4 2013 - - - - - - -
Q1 2014 - - - - - - -
Q2 2014 - - - - - - -
Q3 2014 - - - - - - -
Q4 2014 - - - - - - -
Q1 2015 - - - - - - -
Q2 2015 - - - - - - -
Q3 2015 - - - - - - -
Q4 2015 - - - - - - -
Q1 2016 - - - - - - -
Q2 2016 - - - - - - -
Q3 2016 - - - - - - -
Q4 2016 - - - - - - -
Q1 2017 - - - - - - -
Q2 2017 - - - - - - -
Q3 2017 - - - - - - -
Q4 2017 - - - - - - -
Q1 2018 1,169.41 - 361.40 - 216.53 - 0.62
Q2 2018 1,068.31 - 290.57 - 151.51 - 0.43
Q3 2018 1,145.35 - 354.30 - 207.93 - 0.59
Q4 2018 1,204.57 - 355.74 - 225.34 - 0.64
Q1 2019 1,227.90 5.0 % 404.20 11.8 % 234.08 8.1 % 0.67
Q2 2019 1,157.19 8.3 % 334.70 15.2 % 167.97 10.9 % 0.48
Q3 2019 1,226.74 7.1 % 348.97 (1.5 %) 198.00 (4.8 %) 0.57
Q4 2019 1,404.45 16.6 % 435.67 22.5 % 270.18 19.9 % 0.77
Q1 2020 1,343.34 9.4 % 399.85 (1.1 %) 246.60 5.3 % 0.70
Q2 2020 1,203.01 4.0 % 359.86 7.5 % 192.25 14.5 % 0.55
Q3 2020 1,623.91 32.4 % 558.89 60.2 % 298.80 50.9 % 0.85
Q4 2020 1,691.35 20.4 % 545.81 25.3 % 317.83 17.6 % 0.91
Q1 2021 1,694.79 26.2 % 549.42 37.4 % 319.00 29.4 % 0.91
Q2 2021 1,751.21 45.6 % 551.02 53.1 % 325.40 69.3 % 0.93
Q3 2021 1,836.35 13.1 % 586.42 4.9 % 348.62 16.7 % 1.00
Q4 2021 1,968.13 16.4 % 643.38 17.9 % 383.59 20.7 % 1.10
Q1 2022 1,990.86 17.5 % 658.56 19.9 % 390.51 22.4 % 1.12
Q2 2022 2,014.01 15.0 % 670.88 21.8 % 398.13 22.4 % 1.14

Profitability

Period Gross Margin OIBDA Margin Net Margin Before Unusual Items
Q1 2013 - - -
Q2 2013 - - -
Q3 2013 - - -
Q4 2013 - - -
Q1 2014 - - -
Q2 2014 - - -
Q3 2014 - - -
Q4 2014 - - -
Q1 2015 - - -
Q2 2015 - - -
Q3 2015 - - -
Q4 2015 - - -
Q1 2016 - - -
Q2 2016 - - -
Q3 2016 - - -
Q4 2016 - - -
Q1 2017 - - -
Q2 2017 - - -
Q3 2017 - - -
Q4 2017 - - -
Q1 2018 - - -
Q2 2018 - - -
Q3 2018 - - -
Q4 2018 29.69 % 21.84 % 17.47 %
Q1 2019 30.24 % 22.28 % 17.62 %
Q2 2019 30.60 % 22.42 % 17.64 %
Q3 2019 29.97 % 21.82 % 17.14 %
Q4 2019 30.37 % 22.40 % 17.35 %
Q1 2020 29.60 % 22.52 % 17.20 %
Q2 2020 29.83 % 23.35 % 17.52 %
Q3 2020 31.47 % 24.38 % 18.08 %
Q4 2020 31.81 % 24.44 % 18.01 %
Q1 2021 32.42 % 24.53 % 18.15 %
Q2 2021 32.61 % 24.54 % 18.65 %
Q3 2021 32.02 % 24.56 % 18.80 %
Q4 2021 32.14 % 24.56 % 18.99 %
Q1 2022 32.32 % 24.53 % 19.19 %
Q2 2022 32.77 % 24.65 % 19.47 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Adjusted EPS (Riyal) Book Value (BV)
Q1 2013 - - - -
Q2 2013 - - - -
Q3 2013 - - - -
Q4 2013 - - - -
Q1 2014 - - - -
Q2 2014 - - - -
Q3 2014 - - - -
Q4 2014 - - - -
Q1 2015 - - - -
Q2 2015 - - - -
Q3 2015 - - - -
Q4 2015 - - - -
Q1 2016 - - - -
Q2 2016 - - - -
Q3 2016 - - - -
Q4 2016 - - - -
Q1 2017 - - - -
Q2 2017 - - - -
Q3 2017 - - - -
Q4 2017 - - - -
Q1 2018 350.00 - - 11.82
Q2 2018 350.00 - - 12.26
Q3 2018 350.00 - - 12.86
Q4 2018 350.00 2.29 2.29 12.37
Q1 2019 350.00 2.34 2.34 12.43
Q2 2019 350.00 2.39 2.39 11.79
Q3 2019 350.00 2.36 2.36 12.36
Q4 2019 350.00 2.49 2.49 12.55
Q1 2020 350.00 2.52 2.52 13.25
Q2 2020 350.00 2.59 2.59 13.29
Q3 2020 350.00 2.88 2.88 13.74
Q4 2020 350.00 3.02 3.02 14.03
Q1 2021 350.00 3.22 3.22 14.33
Q2 2021 350.00 3.60 3.60 14.56
Q3 2021 350.00 3.75 3.75 14.86
Q4 2021 350.00 3.93 3.93 15.25
Q1 2022 350.00 4.14 4.14 15.67
Q2 2022 350.00 4.35 4.35 15.98

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Adjusted P/E Price/book
Q1 2013 - - -
Q2 2013 - - -
Q3 2013 - - -
Q4 2013 - - -
Q1 2014 - - -
Q2 2014 - - -
Q3 2014 - - -
Q4 2014 - - -
Q1 2015 - - -
Q2 2015 - - -
Q3 2015 - - -
Q4 2015 - - -
Q1 2016 - - -
Q2 2016 - - -
Q3 2016 - - -
Q4 2016 - - -
Q1 2017 - - -
Q2 2017 - - -
Q3 2017 - - -
Q4 2017 - - -
Q1 2018 - - -
Q2 2018 - - -
Q3 2018 - - -
Q4 2018 - - -
Q1 2019 - - -
Q2 2019 - - -
Q3 2019 - - -
Q4 2019 - - -
Q1 2020 21.77 21.77 4.14
Q2 2020 29.06 29.06 5.67
Q3 2020 33.48 33.48 7.01
Q4 2020 36.14 36.14 7.77
Q1 2021 38.48 38.48 8.65
Q2 2021 45.35 45.35 11.22
Q3 2021 46.46 46.46 11.71
Q4 2021 41.04 41.04 10.58
Q1 2022 46.02 46.02 12.15
Q2 2022 44.60 44.60 12.13

Business Segments (Million)

Compared With The
Period Hospitals Pharmacies Others
Q1 2018 970.00 189.00 10.00
Q2 2018 865.00 174.00 30.00
Q3 2018 908.00 175.00 62.00
Q4 2018 938.00 199.00 68.00
Q1 2019 999.00 208.00 21.00
Q2 2019 916.00 201.00 40.00
Q3 2019 984.00 203.00 40.00
Q4 2019 1,102.00 242.00 60.00
Q1 2020 1,053.00 237.00 53.00
Q2 2020 931.00 209.00 63.00
Q3 2020 1,272.00 261.00 91.00
Q4 2020 1,346.00 294.00 52.00
Q1 2021 1,320.00 313.00 62.00
Q2 2021 1,366.00 315.00 70.00
Q3 2021 1,418.00 338.00 80.00
Q4 2021 1,482.00 389.00 97.00
Q1 2022 1,506.00 417.00 68.00
Q2 2022 1,534.00 407.00 73.00

Analysts Estimates (Million)

Item Q2 2022 (e) Q2 2022 (a) Change‬
Average 383.40 398.13 3.84 %

Estimates vs Actual (Million)

Item Q2 2022 (e) Q2 2022 (a) Change
Riyad Capital 398.00 398.13 0.0 %
SNB Capital 411.00 398.13 (3.1) %
OSOOL AND BAKHEET 380.18 398.13 4.7 %
AlJazira Capital 371.80 398.13 7.1 %
Al Rajhi Capital 356.00 398.13 11.8 %


Financial Ratios
Current
Market Cap (M Riyal) 100,380.00
Enterprise Value (EV) (M) 103,708.16
Shares Outstanding ((M)) 350.00
EPS ( Riyal) (TTM) 6.02
Book Value (BV) ( Riyal) 18.96
Par Value ( Riyal) 10.00
Adjusted P/E (Last12) 48.96
P/E (TTM) 47.63
Price/book 15.13
Return on Average Assets (%) (TTM) 13.8
Return on Average Equity (%) (TTM) 33.2
more

Share Price

Dr. Sulaiman Al Habib Medical Services Group
286.80
3.80 1.34 %

Dr. Sulaiman Al Habib Medical Services Group (SULAIMAN ALHABIB)

More

Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
loader Train
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.